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In 1990, the lipid nanoparticles were invented in the laboratories, the first patent filings took 
place in 1991. The lipid nanoparticles were developed as alternative to traditional carriers 
such as polymeric nanoparticles and liposomes. After 20 years of lipid nanoparticles, the 
present state of development is reviewed - academic progress but also the development state 
of pharmaceutical products for the benefit of patients. Meanwhile many research groups are 
active worldwide, their results are reviewed which cover many different administration 
routes: dermal and mucosal, oral, intravenous/ parenteral, pulmonary but also ocular. The 
lipid nanoparticles are also used for peptide/protein delivery, in gene therapy and various 
miscellaneous applications (e.g. vaccines). The questions of large scale production ability, 
accepted regulatory status of excipients, and - important for the public perception - lack of 
nanotoxicity are discussed, important pre-requisites for the use of each nanocarrier in 
products. Identical to the liposomes, the lipid nanoparticles entered first the cosmetic market, 
product examples are presented. Presently the pharmaceutical product development focuses 
on products for unmet needs and on niche products with lower development costs (e.g. ocular 
delivery), which can be realized also by smaller companies. A pharmaceutical perspective for 
the future is given, but also outlined the opportunities for non-pharmaceutical use, e.g. in 
nutraceuticals. 
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